Pemphigus monoclonal antibody

Details Pemphigus monoclonal antibody Pemphigus monoclonal antibody

2002-09-04

2009-06-23

Ewoldt, G. R (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

07550562

ABSTRACT:
The present invention provides a monoclonal antibody having a pathogenic activity that can induce pemphigus lesion, a peptide specifically recognized by the monoclonal antibody and useful as a therapeutic drug for pemphigus autoimmune disease, etc. As anti-mouse Dsg3 antibody-producing cells are present in the splenocytes of pemphigus vulgaris mouse model constructed by using autoantigen knockout mouse, cell fusion was conducted with the splenocytes of said mouse model and mouse myeloma cells using polyethyleneglycol, hybridomas were constructed, and monoclonal antibodies against Dsg3 were constructed. Among them, a monoclonal antibody having a pathological activity that can induce pemphigus lesions was screened, the base sequence and amino acid sequence in its variable region (heavy chain, light chain) was determined, and the specific epitope part was identified.

REFERENCES:
patent: 08-188540 (1996-07-01), None
Proby et al., 2000, British J. of Dermatology, vol. 142: 321-330.
Ishikawa et al., 1994, Mammalian Genome, vol. 5: 803-804.
Amagai et al., 1992, J. Clin. Invest. vol. 90: 919-926.
Tchernev et al., 2006, Tissue Antigens, vol. 68: 280-286.
Sekiguchi et al.,2000, J Derm. Sci. vol. 23: 197.
K. Tsunoda et al., “Development of anti-desmoglein 2(Dsg3) pathogenic monoclonal antibody using active disease mouse model for pemphigus vulgaris (PV),”J. Invest. Dermatol., vol. 117, No. 2, pp. 349, 028, Aug. 2001.
K. Tsunoda et al., “Production of anti-desmoglein 3 mouse monoclonal antibodies using active disease mouse model for pemphigus,” J.Invest. Dermatol, vol. 114, No. 4, pp. 846, 579, 2000.
M. Amagi et al., “Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus,”J. Clin. Invest. vol. 105, No. 5, p. 625-31, 2000.
M. Amagi et al, “Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice,”J. Clin. Invest., vol. 102, No. 4, p. 775-82, 1998.
M. Amagi et al., “Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion,”Cell, vol. 67, No. 5, p. 869-77, 1991.
K. Tsunoda et al., “A pathogenic antidesmoglein 3 monoclonal antibody recognizes the N-terminal adhesive region of desmoglein 3,”J. Invest. Dermatol., vol. 119, No. 1, pp. 228, 125, Jul. 2002.
M. Ohyama et al., “Immunologic and histopathologic characterization of active disease model mouse for pemphigus vulgaris,”J. Invest. Dermatol., vol. 117, No. 2, pp. 459, 416, Aug. 2001.
H. Ishikawa et al., “Molecular cloning of the mouse desmoglein 3 gene (Dsg3): genomic structure and homology with the human gene,”J. Invest. Dermatol., vol. 106, No. 4, pp. 848, 258, 1996.
Y. Futei et al., “Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris,”J. Invest. Dermatol., vol. 115, No. 5, pp. 829-834, 2000.

Affiliated with

Also associated with

Rating

Pemphigus monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pemphigus monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pemphigus monoclonal antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4120299